remain under-valued follow multipl
updat forecast estim apr
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research apr
estim apr
price data jul
rate updat jul
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
lead drug jakafi initi gain traction
drug approv sever myelofibrosi rare blood disord
jakafi monopoli mf market like continu especi
two lead competitor drug left play field
lacklust pivot trial data expand jakafi label
polycythemia vera late evalu drug
essenti thrombocythemia steroid refractori acut graft
versu host diseas push peak sale
market drug jak inhibitor olumi
baricitinib approv europ rheumatoid arthriti
earli partner
estim ra billion-plu market repres
compel opportun oral treatment like olumi
could support higher treatment penetr rate grow
market oral jak inhibitor xeljanz first market
safeti concern regard seriou infect rate malign
weigh market penetr olumi look slightli
better particular safeti issu though addit black
box label thrombocytosi expect cloud launch
 believ ra market could support multipl jak
inhibitor given high patient churn therapi
olumi phase atop dermat lupu well
compani also robust late-stag pipelin focus primarili
oncolog autoimmun indic provid
attract long-term growth opportun firm
face major trial failur believ rest compani
robust pipelin support long-term growth trajectori
use cash gener success jakafi franchis
build suit asset evalu combin
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
focus discoveri develop small-molecul drug
firm lead drug jakafi treat two type rare blood cancer
partner novarti market drug includ rheumatoid
arthriti treatment olumi licens oncolog drug
iclusig chronic myeloid leukemia pipelin includ broad array
oncolog autoimmun program includ next-gener jak
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
remain under-valued follow
line
first-quart result
expect adjust lower expect
olumi royalti advanc ruxolitinib cream
second late-stag indic maintain
growth jakafi driven mostli volum
keep full-year estim revenu
billion slightli adjust estim
research develop cost year lower
assum olumi royalti long run
opt end fund develop olumi
sever intern pipelin program fund think
logic choic decis impact
tier base olumi royalti increment
royalti could declin slowli given amount
fund program alreadi pass addit
think invest olumi difficult justifi
given drug side effect profil competit
landscap oral jak inhibitor immunolog think
jakafi support narrow moat strong
pipelin oncolog immunolog support posit
moat trend receiv approv jakafi
diseas may data larger studi
chronic acut gvhd come later year next-
gener inhibitor itacitinib also phase studi
gvhd first-lin treatment produc
data acut diseas
ruxolitinib cream vitiligo data come later
quarter dermatolog autoimmun condit
effect treatment vitiligo phase trial
commenc like later year phase alreadi
underway atop dermat encourag
potenti program increas assum
probabl approv see
potenti sale approach billion year
also plan file approv pemigatinib later
year cholangiocarcinoma fgfr alter
nich indic could bode well use patient
alter bladder cancer
tumor beyond pemigatinib grow early-
stage pipelin immuno-oncolog includ
bispecif antibodi enter clinic trial
quarter oral drug recent enter
clinic studi think earli model sale
therapi look forward data
improv growth forecast alreadi ahead
fair valu estim stand per share
olumi market eli lilli receiv
royalti percentag sale addit
develop regulatori mileston project
olumi royalti revenu near million
toward end forecast period also optimist
compani partnership
checkpoint modul program direct gitr
howev yet attribut
valu model enter early-stag
jakafi continu strong perform mf pv
discontinu sanofi mf candid
well lacklust pivot
result gilead momelotinib cti pharma/baxalta
pacritinib believ jakafi near-term growth prospect
improv drug signific first-mov
advantag product could come
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
pipelin candid greater oper leverag
result per share fair valu estim
bear-cas scenario model jakafi struggl
penetr mpn market failur earli stage
asset oper cost result signific
financi burden base case result fair
valu drop per share
myeloprolif neoplasm mpn market
includ mf pv merit narrow econom moat rate
firm heavili depend jakafi sale nearli
revenu recent hit profit within
past year howev lack near-term threat
jakafi domin mf pv popul
incyt strong price power give us confid
compani gener return cost capit
forese futur
strong competit posit thank
jakafi franchis myeloprolif neoplasm
treatment approv food drug
administr myelofibrosi approv
polycythemia vera refractori patient drug
signific price power first-mov advantag
compet pipelin treatment jakafi solid efficaci
safeti profil patient popul high unmet
need allow compani set averag annual price
world-wide jakafi key patent expir
exclud potenti extens give incyt
signific runway build franchis expand
et gvhd indic
pipelin competit thin recent year
forese signific near-term threat
gilead drug momelotinib cti biopharma/baxalta
think approv jakafi polycythemia vera
potenti label expans essenti thrombocythemia
acut gvhd could lead peak sale billion
next-gener itacitinib could mitig potenti
pipelin gener competit futur
valuat exclud incyt ido inhibitor program light
epacadostat phase trial failur metastat
melanoma combin merck inhibitor
keytruda anticip lacklust result remain
trial evalu epacadostat combin
partnership
astrazeneca bristol would provid upsid fair valu
given depend hand market
drug regulatori commerci risk pipelin
believ firm warrant high uncertainti rate
bull-cas scenario assum jakafi success
expand indic greater optim
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
primarili oncolog autoimmun indic
recent partner checkpoint modul
program direct gitr
opportun remain rel unproven incyt
healthi pipelin give firm margin error believ
strategi develop combin oncolog
regimen bode favor competit advantag
rheumatoid arthriti drug olumi receiv multipl
setback last fda approv mg
dose mg black box warn due concern
imbal thrombot event treatment
efficaci olumi ra base top-lin
result jak inhibitor xeljanz first
market despit steep competit believ ra
market could support multipl oral jak inhibitor given
high patient churn therapi potenti
near-term catalyst progress dim
time believ uptak ex-u market remain
drug pacritinib previous led competit
acquisit impact biomedicin earli
celgen reviv anoth competitor program fedratinib
continu believ jakafi set high bar next round
novel molecul
myelofibrosi
 exit partnership
bristol/promedior antifibrot modul
expect use patient toler jakafi
low level platelet fail jakafi
therapi near-term prospect promis
view mani early-stag competitor trial way
includ checkpoint inhibitor keytruda opdivo
howev believ earli candid
signific threat incyt jakafi franchis
robust pipelin mitig threat
futur jakafi sale compani sever early-
late-stag candid focus primarili oncolog
inhibitor provid
think posit moat trend base
potenti jakafi label expans progress
compani robust early-stag pipelin jakafi carv
strong defens market posit
addit label expans pv drug achiev
blockbust statu label expans acut chronic
graft-versus-host-diseas et could boost futur
compani procur
candid immuno-oncolog target posit
well increasingli key therapeut area
compani also sever earlier-stag candid focus
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
jakafi first fda-approv
treatment rare blood disord known
myelofibrosi give strong price power
ojakafi label expans next-gener itacitinib
progress provid near-term catalyst firm
broad array pipelin oncolog
autoimmun program give firm larger margin
error
market upend monopoli
crowd market
thrombocytosi black box warn market
disadvantag
ido inhibitor trial failur melanoma
remov key near-term asset pipelin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
end billion cash
market secur limit debt balanc sheet
howev like biotechnolog compani
histor oper loss high cost
clinic trial research loss financ
larg offer equiti debt secur
collabor research develop fund arrang
develop mileston partner despit
heavi spend expect firm reach
sustain profit jakafi sale intern
royalti off-set high invest
histor post loss due heavi
research develop spend firm current
sound financi shape prolong loss eros
jakafi sale could put financi posit jeopardi
signific risk mani drug candid
never reach market jakafi phase trial failur
pancreat cancer significantli reduc
optimist predict exampl addit new
competitor jakafi could reach market erod
competit posit drug also small
molecul ensur gener competit
difficult stave goe patent melanoma
trial failur highli anticip ido inhibitor
epacadostat combin merck inhibitor
keytruda also highlight development risk associ
biotech compani furthermor baricitinib
demonstr attract profil conveni oral
formul ra market highli competit
demonstr launch pfizer xeljanz
disappoint even though first oral
product market upadacitinib secur
clean prescrib label fda approv expect third
quarter drug could give olumi run
money market olumi approv
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
less efficaci mg dose amid concern thrombot
event mg dose
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ceo/chairman board/
repres date owner name posit common share held report holder issuer
capit research manag compani
new york mellon corp
share
fund
share
fund
hoppenot took ceo join
presid oncolog novarti believ
hoppenot experi establish pharma firm
valuabl pipelin matur firm
transit one-drug start-up matur
diversifi biopharmaceut compani given firm
lack sustain profit past focus
deploy capit research develop
result capital-alloc decis
judg manag howev believ firm
licens agreement eli lilli olumi dictat
favor term compani sharehold alik
respons research
develop cost entitl substanti royalti
mileston payment although execut
 commerci jakafi well without previou
experi view think would
difficult go alon competit rheumatoid arthriti
market also like manag strategi deploy
cash gener jakafi franchis acquir early-stag
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
approv indic rheumatoid arthriti begin
ramp
maintain fve follow share
remain under-valued pipelin progress feb
myelofibrosi drug jakafi strong sale growth
fourth quarter sale million
repres growth almost billion
year growth slightli beat expect
full-year stronger revenu guidanc
line assumpt slightli
rais long-term assumpt expens
also boost probabl approv sever mid-
late-stag pipelin program expect
signific chang fair valu estim firm
narrow moat support jakafi domin
posit moat trend expand jakafi approv
grow late-stag pipelin billion cash
expect firm could use add late-stag
fda review jakafi steroid-refractori graft-versus-
host diseas delay three month
approv expect may signific
addit data gvhd later year
potenti expand steroid-nav patient could
add elig patient jakafi next-
steroid-nav patient itacitinib second half
well addit ruxolitinib jakafi trial acut
pemigatinib
second-lin
cholangiocarcinoma third quarter also enter
pivot studi first-lin cholangiocarcinoma first-lin
bladder cancer year well pan-tumor trial fgf/
cream phase atop dermat data
enter phase vitiligo phase data expect year
olumi also recent met primari endpoint two atop
dermat studi royalti partner lilli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
equival
net properti plant equip
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
